- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02703246
Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hysterectomy is the most commonly performed non-obstetric procedure in women in the United States, with approximately 400,000 hysterectomies performed each year. Minimally invasive techniques have all been shown to have advantages over laparotomy. These include decreased blood loss, faster recovery time, improved postoperative pain and decreased postoperative complications including wound infections, thromboembolism, iatrogenic injuries and incisional hernias. Due to all of these benefits, the volume of minimally invasive procedures has increased significantly over the last ten years making tissue extraction a widely debated topic.
Morcellation is a technique that allows large pieces of tissue to be removed through small incisions and was originally performed either with a scalpel or manual device until the first power/electric morcellators were introduced in 1993. Since then, power morcellation has made 50,000 to 150,000 minimally invasive hysterectomies possible annually. While the former has been an integral part in the treatment of women with large uteri and uterine fibroids, it has recently come under scrutiny due to multiple concerns including dissemination of undetected malignancy, development of iatrogenic myomas as well as increased number of reported complications and death. This has led the US Food and drug administration in April 2014 to issue a statement discouraging the use of laparoscopic power morcellation.
In the face of the growing bias against electronic mechanical morcellators, other approaches must be investigated and promulgated so that patients may still benefit from minimally invasive gynecologic surgeries. The two commonly used methods for tissue extraction are manual morcellation through mini-laparotomy and vaginal morcellation. In the former, a trocar site enlargement or a new up to 1 inch incision is created through which the specimen is brought to the abdominal surface and morcellated with scalpel.In the latter, tissues are removed in the same fashion but via a colpotomy. The investigators intent is to compare manual morcellation methods (vaginal vs abdominal mini-laparotomy) in order to help surgeons choose the best approach for their patient.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington University Medical Faculty Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hysterectomy planned for a benign gynecologic reason
- Patient is scheduled to have surgery with one of the minimally invasive gynecologic surgeons at George Washington University Hospital. (Dr. Moawad, Dr. Marfori, or Dr. Vargas)
- Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH)
- Patient is capable of informed consent
- Patient must be between 18 and 65 years of age
- Uterus greater than 12 centimeters in height and 4 centimeters in width or 12 weeks in size
Exclusion Criteria:
- Hysterectomy is indicated for malignancy
- Procedure is anything other than RA-TLH or TLH
- Surgeon is not one of hte minimally invasive surgeons at GWUH
- Surgery is scheduled for a hospital other than GWUH
- Patient does not meet the age requirements.
- Patient is not capable of informed consent
- Uterus is less than 12 cm in heightand 4 cm in width
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: abdominal morcellation
Women randomized to this group will undergo abdominal morcellation.
|
patients will be randomized to receive abdominal morcellation
|
|
Active Comparator: vaginal morcellation
Women randomized to this group will undergo vaginal morcellation.
|
patients will be randomized to receive vaginal morcellation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total operative time
Time Frame: Perioperative
|
Time (in minutes) from when first cut is made until last suture is made.
|
Perioperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Loss
Time Frame: perioperative
|
as measured in cubic centimeters (cc)
|
perioperative
|
|
Intraoperative complications
Time Frame: perioperative
|
Intraoperative complications include: Organ injury (bladder, bowel, vaginal laceration), Estimated Blood Loss>1000cc, and conversion to laparotomy
|
perioperative
|
|
Post-operative complications
Time Frame: as recorded between end of operation and 4 weeks post operation
|
Post-operative complications include: Reoperation, Intensive Care Unit (ICU) admission, Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE), transfusion, Readmission, Bowel obstruction/ileus, Incision seroma/cellulitis/hematoma/separation/hernia, and cuff cellulitis/abcess/dehiscence/granulation tissue
|
as recorded between end of operation and 4 weeks post operation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gaby Moawad, MD, George Washington University Medical Faculty Associates
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 091553
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibroids
-
Virtual Tribunal MonasteryWithdrawnUterine Fibroids Affecting Pregnancy | Uterine Fibroids - 1St Diagnosis | Uterine Fibroid DegeneratedUnited States
-
Shenzhen Kangzhe Biotechnology Co., Ltd.RecruitingUterine Fibroids With MenorrhagiaChina
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Assistance Publique Hopitaux De MarseilleRecruiting
-
IceCure Medical Ltd.Withdrawn
-
Duke UniversityCompleted
-
Kaohsiung Medical UniversityNot yet recruiting
-
Trieu, Nguyen Thi, M.D.TRAN MINH DUC, MDCompletedUterine Fibroids Affecting PregnancyVietnam
-
University Hospital TuebingenCompletedOne or More Uterine FibroidsGermany
-
Elizabeth A. StewartCompletedUterine Fibroids | Myomas | Uterine Leiomyomas | FibroidsUnited States
Clinical Trials on abdominal morcellation
-
University Magna GraeciaCompleted
-
Ege UniversityCompleted
-
Università degli Studi dell'InsubriaNot yet recruiting
-
Ege UniversityRecruitingLaparoscopic HysterectomyTurkey (Türkiye)
-
University Hospital, Strasbourg, FranceCompletedEndometrial PolypsFrance
-
ARKSurgicalUnknown
-
I.M. Sechenov First Moscow State Medical UniversityUnknownBladder CancerRussian Federation
-
National Taiwan University HospitalCompletedSurgical Procedure, UnspecifiedTaiwan
-
Cairo UniversityCompletedHysterectomy, Benign Uterine DiseasesEgypt
-
Milton S. Hershey Medical CenterCompletedAcute Lung InjuryUnited States, Canada